NEW YORK (GenomeWeb) – GenMark Diagnostics reported today after the close of the market that its fourth quarter revenues rose 34 percent year over year.

For the three months ended Dec. 31, 2015, the company reported revenues of $13.2 million compared to $9.8 million in Q4 2014, beating analysts' consensus estimate of $12.3 million for the quarter. Product sales accounted for almost all of the revenue in the quarter, and the company said it placed 17 additional XT-8 analyzers in end-user laboratories for a total of 633 analyzers in the US market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.